Implications of LAG3 and CTLA4 immune checkpoints beyond PD-1/PD-L1 as a potential target in determining the prognosis of uveal melanoma patients.

MLA

Kashyap, Seema, et al. “Implications of LAG3 and CTLA4 Immune Checkpoints beyond PD-1/PD-L1 as a Potential Target in Determining the Prognosis of Uveal Melanoma Patients.” The British Journal of Ophthalmology, vol. 108, no. 6, May 2024, pp. 903–12. EBSCOhost, https://doi.org/10.1136/bjo-2022-322913.

APA

Kashyap, S., Singh, M. K., Kumar, N., Jha, J., Lomi, N., Meel, R., Bakhshi, S., Sen, S., & Singh, L. (2024). Implications of LAG3 and CTLA4 immune checkpoints beyond PD-1/PD-L1 as a potential target in determining the prognosis of uveal melanoma patients. The British Journal of Ophthalmology, 108(6), 903–912. https://doi.org/10.1136/bjo-2022-322913

Chicago

Kashyap, Seema, Mithalesh Kumar Singh, Nikhil Kumar, Jayanti Jha, Neiwete Lomi, Rachna Meel, Sameer Bakhshi, Seema Sen, and Lata Singh. 2024. “Implications of LAG3 and CTLA4 Immune Checkpoints beyond PD-1/PD-L1 as a Potential Target in Determining the Prognosis of Uveal Melanoma Patients.” The British Journal of Ophthalmology 108 (6): 903–12. doi:10.1136/bjo-2022-322913.